Macrocure (MCUR) Phase III Clinical Trial of CureXcell Missed Primary Endpoint
Macrocure Ltd. (NASDAQ: MCUR) today announced that results from a pivotal Phase 3 multicenter, randomized, double-blind, parallel-group, sham-controlled study (MC-102...




